Analysts say Netflix investors should ‘buy the pullback,’ as password sharing ‘supercharges’ subscriber growth
The company added 5.9 million subscribers in the quarter in a sign that its password-sharing crackdown and ad tier are generating new subscribers.
Wheat prices soar for a third day as Russia-Ukraine tensions stoke fears of major food crisis
Wheat prices rose for a third straight day on Thursday after Russia threatened to treat ships heading for Ukrainian ports as military cargo carriers.
Kenvue shares fall even as J&J spinoff beats estimates in first quarterly earnings since IPO
J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the consumer health spinoff’s business for the time being.
American Airlines raises 2023 profit forecast after strong second quarter
Record revenue of $14.06 billion topped analysts’ expectations and was up 4.7% from a year earlier.
Analysts take Tesla results in stride, but margin concerns remain
Several big banks are maintaining a neutral outlook on the stock after its significant rally this year.
Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge
The results come amid investor anxiety over the thousands of lawsuits claiming that J&J’s talc-based baby powder and other products caused cancer.
Morgan Stanley upgrades Anheuser-Busch InBev, says it’s attractively valued after Bud Light controversy
A decline in commodity prices should boost the parent company behind Bud Light. The U.S.-listed shares of the beverage company are down about 2.7% this year.
Netflix earnings showcase strength as the rest of the media industry struggles
Netflix’s core business continues to chug along as the rest of the media and entertainment industry searches for new growth.
IBM reports earnings beat, but misses on revenue
IBM’s data and artificial intelligence products showed the fastest expansion, growing 10% from a year earlier, the company said.
Pfizer Group B strep vaccine for infants returns encouraging mid-stage trial results
Pfizer is among several drugmakers racing to develop the world’s first shot targeting Group B strep disease, which kills thousands of infants each year.
